Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

Dollar Index towards reversal: what are the prospects for Bitcoin?

Between today and Wednesday, international financial markets might witness...

Bitcoin tax payments enter Congress spotlight with new U.S. proposal

A new congressional proposal aims to let Americans use...

Samourai Wallet founder seeks Trump pardon after prison sentences

Founder of the privacy-focused Samourai Wallet is seeking a...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.